Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab.

: Nivolumab has been shown to be an effective treatment for metastatic renal cell carcinoma (mRCC); however, patient responses vary considerably. The objective of this study is to evaluate the prognostic value of the C-PLAN index in predicting survival outcomes for patients with mRCC treated with nivolumab. : This retrospective cohort study included 81 mRCC patients previously treated with tyrosine kinase inhibitors who subsequently received nivolumab. The C-PLAN index, which includes C-reactive protein, performance status, lactate dehydrogenase, albumin, and derived neutrophil-to-lymphocyte ratio, was used to classify patients into "good" and "poor" prognostic groups. : The median overall survival (OS) was 22 months, and the median progression-free survival (PFS) was 6.7 months. Patients in the "poor" C-PLAN group exhibited significantly shorter OS and PFS than those in the "good" group (median OS: 13 vs. 31 months, = 0.003; median PFS: 3 vs. 10 months, = 0.007). The C-PLAN index was identified as an independent predictor of both OS (HR = 1.19, 95% CI: 1.11-3.43, = 0.020) and PFS (HR = 1.71, 95% CI: 1.04-2.78, = 0.032) in multivariate analysis. : These findings suggest that the C-PLAN index may serve as a valuable prognostic tool, offering insights into survival outcomes for patients undergoing nivolumab therapy. Further prospective and multicenter studies are warranted to validate its clinical utility.